This article is more than 5 years old. Information may no longer be current.
FDA clears MultiColor imaging for Spectralis
The U.S. Food and Drug Administration has cleared MultiColor Scanning Laser Imaging for all Spectralis models, according to a press release from Heidelberg Engineering.
The laser fundus imaging modality uses infrared, green and blue laser reflectance images to display different retinal structures.
The high-contrast fundus images can display diagnostic information even in patients with cataracts or nystagmus. The images are similar to those of color fundus photographs but can help identify pathologies that may be difficult to see on fundus photos, according to the release.
“The MultiColor module expands the versatility of the Spectralis product family, ranging from our standard Spectralis OCT up to the Spectralis HRA+OCT, which provides multimodality laser video angiography and SD-OCT imaging in one device, all models using confocal scanning laser, real-time active eye tracking and noise reduction technology,” Kester Nahen, PhD, vice president of Global Marketing and Business Development of Heidelberg Engineering, told Ocular Surgery News.
Heidelberg Engineering will showcase the MultiColor module at its exhibit booth at the American Academy of Ophthalmology meeting, he said.